EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications

Maciej Gonciarz iD, Benita Wiatrak iD, Iga Lombard, Łukasz Konecki, Joanna Sarbinowska iD

Journal of Pineal Research · 2026-01 · 78 (1)

DOI: 10.1111/jpi.70101 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pineal Research, online erschienen am 04.12.2025. Verfasst von Maciej Gonciarz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Internal Medicine, Military Institute of Medicine - National Research Institute, Warsaw, Poland. Hauptthemen laut MEDLINE: Melatonin, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrointestinal (GI) cancers remain a leading cause of global morbidity and mortality, necessitating novel therapeutic strategies. Melatonin (MEL), an indoleamine with pleiotropic biological activities, has emerged as a promising adjuvant in oncology due to its antiproliferative, proapoptotic, and antioxidant properties. This review synthesizes current evidence on MEL's molecular mechanisms in GI carcinogenesis, including modulation of NF‐κB, PI3K/AKT, and Wnt/β‐catenin pathways, suppression of reactive oxygen species (ROS), and regulation of circadian rhythm‐related genes (e.g., CLOCK, BMAL1). Preclinical studies demonstrate that MEL enhances chemoradiotherapy efficacy‐reducing tumor volume by 70% in murine colorectal models and decreasing 5‐fluorouracil (5‐FU) resistance via miR‐532‐3p/β‐catenin axis modulation. Clinical trials report a 23%–41% risk reduction in colorectal cancer among shift workers with MEL supplementation and a 53% decrease in radiotherapy‐induced oral mucositis. Despite promising data, limitations persist: fewer than 15% of clinical trials focus on GI cancers, dosing remains unstandardized (10–40 mg/day), and molecular heterogeneity (e.g., KRAS mutations in pancreatic cancer) may limit therapeutic responses. Future research must prioritize phase III trials, chronotherapy optimization, and biomarker‐driven approaches, including MT1/MT2 receptor expression and microbiome profiling. Given its low toxicity and putative synergy with immunotherapies, MEL should be regarded as an adjunct under investigation rather than an established option; to date, no GI‐specific phase III randomized trials exist, and clinical signals come primarily from small, heterogeneous cohorts. Dosing is unstandardized and limited by low oral bioavailability (first‐pass) and possible pharmacogenomic variability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelatoninGastrointestinal NeoplasmsHumansAnimals

Stichwörter der Autor:innen

antineoplastic agentsantioxidant activitygastrointestinal cancermelatonintherapy

Substanzen

Melatonin

Autor:innen und Institutionen

  • Department of Gastroenterology and Internal Medicine, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
  • Department of Pharmacology, Wroclaw Medical University, Wroclaw, Poland.

ORCID-Profile: Maciej Gonciarz, Benita Wiatrak, Joanna Sarbinowska

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Gonciarz, M., Wiatrak, B., Lombard, I., Konecki, Ł., & Sarbinowska, J. (2026). Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications. Journal of Pineal Research, 78(1). https://doi.org/10.1111/jpi.70101

Vancouver

Gonciarz M, Wiatrak B, Lombard I, Konecki Ł, Sarbinowska J. Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications. Journal of Pineal Research. 2026;78(1). doi:10.1111/jpi.70101

BibTeX
@article{Gonciarz2026,
  author = {Gonciarz, Maciej and Wiatrak, Benita and Lombard, Iga and Konecki, Łukasz and Sarbinowska, Joanna},
  title = {Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications},
  journal = {Journal of Pineal Research},
  year = {2026},
  volume = {78},
  number = {1},
  doi = {10.1111/jpi.70101}
}
Kostenlos starten →